Pfizer Inc is developing CP-751871, a fully human IgG2 antibody specific for the type I insulin-like growth factor receptor for the potential treatment of various cancers and rheumatoid arthritis. A phase Ib/II clinical trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC is underway.
|Original language||English (US)|
|Number of pages||6|
|Journal||Current Opinion in Molecular Therapeutics|
|State||Published - Jun 1 2007|